Skip to content
2000
Volume 14, Issue 12
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

The advent of anti-Tumor Necrosis Factor (TNF) therapy has changed the way of treating inflammatory bowel disease (IBD). However, primary and secondary failure are relatively frequent with all anti-TNF agents, which are available only as parenteral agents. Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved by the FDA for rheumatoid arthritis. First data in IBD are promising, especially in ulcerative colitis. Ongoing clinical trials in both UC and Crohn’s disease (CD) are needed to further explore its efficacy in CD and to better assess its safety profile.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/13894501113149990160
2013-11-01
2025-06-08
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/13894501113149990160
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test